CRN 04777
Alternative Names: CRN-04777Latest Information Update: 10 Aug 2023
At a glance
- Originator Crinetics Pharmaceuticals
- Class Antihypoglycaemics; Small molecules
- Mechanism of Action Somatostatin receptor 5 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Congenital hyperinsulinism
Most Recent Events
- 30 Jun 2023 Discontinued - Phase-I for Congenital-hyperinsulinism (In volunteers) in Germany (PO)
- 24 Oct 2022 Crinetics submits IND application to the US FDA in Congenital hyperinsulinism
- 06 Oct 2022 CRN 04777 receives Innovation Passport designation under Innovative Licensing and Access Pathway (ILAP) from the MHRA for Congenital hyperinsulinism in the United Kingdom